Novo launches Saxenda in US, sees more launches in 2015

April 22, 2015 3:28 PM

2 0

COPENHAGEN (Reuters) - Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.

It will cost $1,068 per month, and the price paid by the individual patient will depend on his or her health insurance, the company said in an email to Reuters.

Also read: McDonald’s Revenue Tops Estimates as Breakfast Boosts U.S

Read more

To category page